H.C. Wainwright Downgrades Shattuck Labs (STTK) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- BuzzFeed cuts 35% of workforce in restructuring move
TD Cowen Reiterates Buy Rating on Shattuck Labs (STTK)
October 1, 2024 9:28 AM EDTTD Cowen analyst Marc Frahm reiterated a Buy on Shattuck Labs (NASDAQ: STTK).
The analyst commented, "STTK has discontinued the SL-172154 program in HR-MDS/AML based on uncompelling OS separation vs. historical controls. The company is pivoting to a series of anti-DR3... More
Shattuck Labs (STTK) Provides Company Update and Announces SL-325
October 1, 2024 6:32 AM EDTShattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with cancer and chronic immune-related diseases, today announced a strategic pipeline prioritization to include the discontinuation of its clinical program, SL-172154. The Company will turn its focus to SL-325, its DR3 antagonist antibody, and plans initial clinical development in patients with IBD, where TL1A/DR3 blocking antibodies have demonstrated compelling monotherapy efficacy.
We are disappointed that the promising complete remission rates we... More
